Cost-Effectiveness of Recombinant Activated Factor VII as Adjunctive Therapy for Bleeding Control in Severely Injured Trauma Patients in Germany

European Journal of Trauma and Emergency Surgery : Official Publication of the European Trauma Society
Rolf RossaintNovoSeven® Trauma Study Group

Abstract

The purpose of this study was to assess the cost-effectiveness of recombinant activated factor VII (rFVIIa) as adjunctive therapy for the control of bleeding in patients with severe blunt trauma injuries in Germany. The primary outcome measure was incremental cost per quality-adjusted life-year (QALY) gained. We developed a cost-effectiveness model based on patient-level data from a 30 day international, randomized, placebo-controlled phase II trial. The data were supplemented with secondary data from the German Trauma Register and German life tables to estimate lifetime costs and benefits. We assumed that the non-significant difference in mortality observed in the phase II trial of 5% in favor of rFVIIa could be verified in the ongoing, much larger follow-up trauma study. We adopted the perspective of third-party payers in Germany, and included all trauma-related healthcare costs. The incremental cost per QALY gained with rFVIIa relative to placebo was e29,451. The probability that this was below e30,000 and e40,000 was 51 and 58%, respectively. The estimates were sensitive to the differences observed in mortality and the applied discount rate. Based on preliminary evidence from a phase II trial, we conclude that, relative to ...Continue Reading

References

Sep 1, 1991·The British Journal of Surgery·C J WatsonA K Dixon
Feb 1, 1995·The Journal of Trauma·A SauaiaP T Pons
Jan 1, 1994·Archives of Surgery·A SauaiaD C Lezotte
Oct 9, 1996·JAMA : the Journal of the American Medical Association·L B RussellM C Weinstein
Sep 25, 1999·The Journal of Trauma·J SéguinP C Hébert
Dec 10, 1999·Lancet·G KenetU Martinowitz
Jun 13, 2000·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·M Al DouriR Borum Andreasen
Mar 15, 2002·The American Journal of Medicine·Pieter W KamphuisenTom I F M Bloemen
Jun 5, 2003·The Journal of Trauma·Debra L MaloneLena M Napolitano
May 26, 2004·Transfusion·John J ComoJohn R Hess
Jun 24, 2004·The Journal of Trauma·Roshni KulkarniSheri LaFrance
Sep 16, 2004·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Hans-Georg EichlerBengt Jönsson
Oct 30, 2004·The Journal of Trauma·Richard P DuttonThomas M Scalea
Jun 23, 2005·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Ante TonkicStjepan Mise

❮ Previous
Next ❯

Citations

Mar 30, 2010·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Terje VeelHilde Pleym
Sep 11, 2007·Emergency Medicine Clinics of North America·Michael N CocchiMichael W Donnino
Apr 11, 2018·BMC Health Services Research·Fabia Mareike Gansen
Sep 23, 2008·Expert Review of Medical Devices·Athanasios KoukakisAlexander Amini
Mar 8, 2011·The Journal of Trauma·Michael C ChristensenStephen Morris
Feb 17, 2021·Critical Care Medicine·Vincent I LauBram Rochwerg

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.